Skip to content
LogiclyLogicly

Free for 14 days. No card to start.

Get started free

C7A Malignant neuroendocrine tumors

C7A is the ICD-10-CM code family for Malignant neuroendocrine tumors: 23 codes, 22 of which can lead a home health claim.

Codes in family

23

Can lead a claim

22

Cannot lead a claim

1

What CMS assigns to C7A

22 of the 23 codes group to MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases; 1 is assigned no clinical group. 22 of the 23 count toward the Merkel Cell and Neuroendocrine Carcinoma comorbidity subgroup; 1 is assigned none. 22 of the 23 can lead a claim.

  • Merkel Cell and Neuroendocrine Carcinoma

Every code in C7A

Descriptions are CDC’s FY2027 wording; where CMS’s grouper abbreviates one, its form is shown beneath.

CodeDescriptionPrimary positionClinical groupComorbidity subgroup
C7A.0 Malignant carcinoid tumors
C7A.00Malignant carcinoid tumor of unspecified siteCannot lead a claimPrincipal diagnosis not assigned to a clinical groupNoneNone
C7A.01 Malignant carcinoid tumors of the small intestine
C7A.010Malignant carcinoid tumor of the duodenumCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.011Malignant carcinoid tumor of the jejunumCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.012Malignant carcinoid tumor of the ileumCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.019Malignant carcinoid tumor of the small intestine, unspecified portionCMS: Malignant carcinoid tumor of the sm int, unsp portionCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.02 Malignant carcinoid tumors of the appendix, large intestine, and rectum
C7A.020Malignant carcinoid tumor of the appendixCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.021Malignant carcinoid tumor of the cecumCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.022Malignant carcinoid tumor of the ascending colonCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.023Malignant carcinoid tumor of the transverse colonCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.024Malignant carcinoid tumor of the descending colonCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.025Malignant carcinoid tumor of the sigmoid colonCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.026Malignant carcinoid tumor of the rectumCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.029Malignant carcinoid tumor of the large intestine, unspecified portionCMS: Malignant carcinoid tumor of the lg int, unsp portionCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.09 Malignant carcinoid tumors of other sites
C7A.090Malignant carcinoid tumor of the bronchus and lungCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.091Malignant carcinoid tumor of the thymusCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.092Malignant carcinoid tumor of the stomachCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.093Malignant carcinoid tumor of the kidneyCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.094Malignant carcinoid tumor of the foregut, unspecifiedCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.095Malignant carcinoid tumor of the midgut, unspecifiedCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.096Malignant carcinoid tumor of the hindgut, unspecifiedCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.098Malignant carcinoid tumors of other sitesCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.1Malignant poorly differentiated neuroendocrine tumorsCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma
C7A.8Other malignant neuroendocrine tumorsCan lead a claimKMerkel Cell and Neuroendocrine Carcinoma

Sources: CMS HH PPS Grouper Software (opens in a new tab) v07.2.26, effective 2026-10-01, for the clinical group, comorbidity subgroup, code-first conventions and primary-position flags; CDC NCHS ICD-10-CM FY2027 (opens in a new tab) code descriptions for the family title and code wording. This is the crosswalk Medicare runs a claim through. Grouping also depends on admission source, timing, the OASIS functional items and the rest of the diagnosis list.